163 related articles for article (PubMed ID: 9869107)
1. Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
Van den Brande P; De Ruysscher D; Vansteenkiste J; Spaas P; Specenier P; Demedts M
Lung Cancer; 1998 Oct; 22(1):45-53. PubMed ID: 9869107
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
[TBL] [Abstract][Full Text] [Related]
3. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
[TBL] [Abstract][Full Text] [Related]
4. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
Vansteenkiste J; Vandebroek J; Mariën S; Roex L; Bertrand P; Bockaert J; De Beukelaar T; Deman R; De Muynck P; Ulrichts H
Lung Cancer; 1995 Dec; 13(3):295-303. PubMed ID: 8719069
[TBL] [Abstract][Full Text] [Related]
6. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
[TBL] [Abstract][Full Text] [Related]
9. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
Tan EH; Wee J; Ang PT; Fong KW; Leong SS; Khoo KS; Tan T; Lee KS; Eng P; Hsu A; Tan YK; Chua EJ; Ong YY
Acta Oncol; 1999; 38(8):1005-9. PubMed ID: 10665753
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer.
Wolf M; Hans K; Becker H; Hässler R; von Bültzingslöwen F; Goerg R; Klaasen HA; Dannhäuser J; Holle R; Pfab R
Semin Oncol; 1994 Jun; 21(3 Suppl 4):42-7. PubMed ID: 8209276
[TBL] [Abstract][Full Text] [Related]
12. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
Kodani T; Ueoka H; Kiura K; Tabata M; Takigawa N; Segawa Y; Moritaka T; Hiraki S; Harada M; Tanimoto M
Lung Cancer; 2002 Jun; 36(3):313-9. PubMed ID: 12009244
[TBL] [Abstract][Full Text] [Related]
13. [Optimization of combined radiotherapy and chemotherapy in treatment of non-small cell lung carcinoma].
Bretel JJ; Arriagada R; Le Chevalier T; Baldeyrou P; Grunenwald D; Le Péchoux C; Pellae-Cosset B; Ruffié P
Cancer Radiother; 1997; 1(2):148-53. PubMed ID: 9273186
[TBL] [Abstract][Full Text] [Related]
14. Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
Vansteenkiste JF; De Leyn PR; Deneffe GJ; Lievens YN; Nackaerts KL; Van Raemdonck DE; van der Schueren E; Lerut TE; Demedts MG
Ann Oncol; 1998 Mar; 9(3):261-7. PubMed ID: 9602259
[TBL] [Abstract][Full Text] [Related]
15. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer.
Ardizzoni A; Grossi F; Scolaro T; Giudici S; Foppiano F; Boni L; Tixi L; Cosso M; Mereu C; Ratto GB; Vitale V; Rosso R
Br J Cancer; 1999 Sep; 81(2):310-5. PubMed ID: 10496358
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.
Kubota K; Tamura T; Fukuoka M; Furuse K; Ikegami H; Ariyoshi Y; Kurita Y; Saijo N
Ann Oncol; 2000 Apr; 11(4):445-50. PubMed ID: 10847464
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
Takeda K; Negoro S; Tanaka M; Fukuda H; Nakagawa K; Kawahara M; Semba H; Kudoh S; Sawa T; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2011 Jan; 41(1):25-31. PubMed ID: 20802006
[TBL] [Abstract][Full Text] [Related]
20. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
